| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5202333 | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Apr, 2015
(9 years ago) | |
|
US5202333 (Pediatric) | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Oct, 2015
(8 years ago) | |
| US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
|
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
|
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(2 months from now) | |
Aloxi is owned by Helsinn Hlthcare.
Aloxi contains Palonosetron Hydrochloride.
Aloxi has a total of 28 drug patents out of which 15 drug patents have expired.
Expired drug patents of Aloxi are:
- US5202333
- US5202333*PED
- US7960424
- US8598219
- US9066980
- US8729094
- US9457021
- US7947725
- US9125905
- US8518981
- US9439854
- US8598218
- US9173942
- US9457020
- US7947724
Aloxi was authorised for market use on 29 February, 2008.
Aloxi is available in capsule;oral, injectable;intravenous dosage forms.
Aloxi can be used as prevention of chemotherapy-induced nausea and vomiting.
The generics of Aloxi are possible to be released after 30 July, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: Prevention of chemotherapy-induced nausea and vomiting
Dosage: INJECTABLE;INTRAVENOUS; CAPSULE;ORAL
ALOXI family patents
